Drug ototoxicity limits the quality of life of patients after treatment, having serious
consequences, especially for psychosocial development of children. Although the ototoxicity …

The Ototoxicity Working Group of Pharmaceutical Interventions for Hearing Loss defined
ototoxicity as damage to the inner ear, targeting cochlear and vestibular structures as well as …

Ototoxicity is a trait shared by aminoglycoside and macrolide antibiotics, loop diuretics,
platinum-based chemotherapeutic agents, some NSAIDs and antimalarial medications …

Purpose This review article summarizes our current understanding of the mechanisms
underlying acquired hearing loss from hospital-prescribed medications that affects as many …

Ototoxicity may be defined as the tendency of certain therapeutic agents and other chemical
substances to cause functional impairment and cellular de generation of the tissues of the …

Aminoglycosides, cisplatin, and non-steroidal anti-inflammatory drugs (NSAIDs) are widely
used pharmacological agents. There is a possibility, however, that the use of these agents …

Ototoxicity is a well‐established toxicity associated with a subgroup of antineoplastic
therapies that includes platinum chemotherapy, radiation or surgery involving the ear and …

Purpose The platinum chemotherapy agents cisplatin and carboplatin are widely used in the
treatment of adult and pediatric cancers. Cisplatin causes hearing loss in at least 60% of …

Ototoxicity refers to damage of inner ear structures (ie, the cochlea and vestibule) and their
function (hearing and balance) following exposure to specific in-hospital medications (ie …

Objective In an era of increasing polypharmacy, adverse drug effects such as ototoxicity
have significant public health implications. Despite the availability of evidence, many health …